THE EFFECT OF FIRST-LINE BASED ON PLATIN AND TAXANE CHEMOTHERAPY ON DENDRITIC CELLS IN WOMEN SUFFERING FROM OVARIAN CANCER

被引：0
|
作者：
Kotarski, J. [1 ]
Wertel, I. W. I. [1 ]
Polak, G. P. G. [1 ]
机构：
[1] Med Univ Lublin, Chair & Dept Oncol Gynaecol & Gynaecol 1, Lublin, Poland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line chemotherapy in advanced ovarian cancer:: State of the art and future aspects
    du Bois, A
    Lück, HJ
    Bauknecht, T
    ONKOLOGIE, 1999, 22 (04): : 269 - 280
  • [32] Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer - A systematic review with melaanalyses
    Elit, Laurie
    Oliver, Thomas K.
    Covens, Allan
    Kwon, Janice
    Fung, Michael -Kee Fung
    Hirte, Holger W.
    Oza, Amit M.
    CANCER, 2007, 109 (04) : 692 - 702
  • [33] Bevacizumab combined with a taxane and a platinum agent as first-line treatment for advanced-stage ovarian cancer
    Kato, Kazuyoshi
    ANNALS OF ONCOLOGY, 2018, 29 : 30 - 30
  • [34] Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
    Slaughter, Katrina N.
    Thai, Theresa
    Penaroza, Shayla
    Benbrook, Doris M.
    Thavathiru, Elangovan
    Ding, Kai
    Nelson, Tina
    McMeekin, D. Scott
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 11 - 15
  • [35] Class 111 β-tubulin as a predictive marker for taxane-based first-line palliative chemotherapy in recurrent or metastatic gasiric cancer
    Hwang, Jun-Eul
    Kim, Dae-Eun
    Shim, Hyun-Jeong
    Bae, Woo Kyun
    Cho, Sang-Hee
    Chung, Ik-Joo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] Unmet needs of women living with ovarian cancer after first-line treatment
    Peate, Michelle
    Marino, Jennifer
    Leong, Janelle
    Hegarty, Sue
    PSYCHO-ONCOLOGY, 2018, 27 : 51 - 51
  • [37] Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma
    Beussel, S.
    Hasenburg, A.
    Bogatyreva, L.
    Hauschke, D.
    Werner, M.
    Lassmann, S.
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (01) : 29 - 35
  • [38] Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer
    Sugiyama, T
    Yakushiji, M
    Kamura, T
    Ikeda, M
    Umesaki, N
    Hasegawa, K
    Ishikawa, M
    Saji, F
    Hiura, M
    Takahashi, T
    Sato, S
    Ochiai, K
    Kikkawa, F
    Takeuchi, S
    Ohashi, Y
    Noda, K
    ONCOLOGY, 2002, 63 (01) : 16 - 22
  • [39] First-line chemotherapy with carboplatin, cisplatin and cyclophosphamide (CCC) in advanced ovarian cancer (AOC)
    Edelmann, DZ
    Peretz, T
    Barak, V
    Anteby, SO
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 520 - 520
  • [40] Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer
    duBois, A
    Luck, HJ
    Meier, W
    Mobus, V
    Costa, S
    Richter, B
    Bauknecht, T
    Warm, M
    Schroeder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : 28 - 33
12345